Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04110496
Other study ID # RTX-134-01
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date January 29, 2020
Est. completion date December 1, 2022

Study information

Verified date December 2022
Source Rubius Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the safety and tolerability of RTX-134 in adult patients with PKU.


Description:

This is a Phase 1b first-in-human trial in adult subjects with PKU. The primary objective of this study is to evaluate the safety and tolerability of RTX-134 following intravenous administration of a single dose. RTX-134 consists of allogeneic human red cells expressing the AvPAL (Anabaena variabilis phenylalanine ammonia lyase) gene inside the cell. The trial is designed to determine a preliminary dose and inform a dosing schedule that is deemed safe, tolerable, and potentially effective. Four dose levels are planned, additional dose levels may be explored. Following administration, subjects will be monitored until 28 days after last detection of RTX-134. Detection of RTX-134 will be evaluated using multiple pharmacokinetic (PK) and pharmacodynamic (PD) assessments including measurement of trans-cinnamic acid (tCA).


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date December 1, 2022
Est. primary completion date December 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria 1. Age 18 years or older with: 1. A clinical diagnosis of PKU, and 2. Average blood phenylalanine level = 600 µmol/L based on 2 assessments up to 3 weeks apart during the 6-month period before Day 0 (per available data) 2. Stable diet, including medical formula 3. Must be a man or a woman not of childbearing potential and agree to use adequate contraception throughout and for one year following study participation. 4. Adequate organ function 5. Negative antibody detection on type and screen and no evidence of clinical hemolysis Exclusion Criteria 1. Known hypersensitivity to any component of study treatment 2. Prior treatment with Pegaliase 3. Start of sapropterin dihydrochloride within 3 weeks of study dosing 4. Use of an investigational agent within 28 days of study dosing 5. Concurrent participation in an interventional trial involving ongoing treatment, including placebo. 6. Infections requiring antimicrobial treatment within 7 days of study dosing 7. Chronic infections, such as HIV, hepatitis B, or untreated hepatitis C 8. Conditions that may alter survival of red blood cells, (e.g., autoimmune diseases, splenectomy, etc) 9. Pregnant or breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RTX-134
RTX-134 is a cellular therapy containing AvPAL

Locations

Country Name City State
United States Children's Hospital Colorado Aurora Colorado

Sponsors (1)

Lead Sponsor Collaborator
Rubius Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the safety and tolerability of RTX-134 as measured by frequency of treatment emergent adverse events Baseline to 28 days after last detection of RTX-134
Primary To correlate dose with percent reduction in serum phenylalanine levels relative to baseline Baseline to 28 days after last detection of RTX-134
Primary To determine a preliminary dose to achieve serum phenylalanine levels < 600 µmol/L Baseline to 28 days after last detection of RTX-134
Primary To determine a preliminary dose to achieve serum phenylalanine levels < 360 µmol/L Baseline to 28 days after last detection of RTX-134
Primary To evaluate the pharmacokinetics of RTX-134 as measured by presence of AvPal expressing red cells, AvPAL protein in red cells and serum, and AvPAL enzymatic activity. Baseline to 28 days after last detection of RTX-134
See also
  Status Clinical Trial Phase
Recruiting NCT05998109 - PheCheck Feasibility Study
Not yet recruiting NCT04433728 - Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.
Completed NCT01209819 - Bone Mineral Density in Adults With Hyperphenylalaninemia N/A
Active, not recruiting NCT05174559 - Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU) N/A
Not yet recruiting NCT04969809 - Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients N/A
Recruiting NCT04404530 - Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
Recruiting NCT05827536 - Open-label, Randomized, 2-way Crossover, Monocentric, Controlled Study to Evaluate the Effect on Daily PHE Fluctuation of PKU GOLIKE Versus SoC in Patients With PKU. N/A
Active, not recruiting NCT05971563 - Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT04368624 - PKU Skin Stripping
Completed NCT04452513 - A Prospective Clinical Study of Phenylketonuria (PKU)
Completed NCT05497050 - The Effect of Nursing Empowerment Program N/A
Completed NCT04943393 - Remote Neurocognitive and Psychological Assessment in PKU
Completed NCT05096988 - Evaluation of PKU Sphere Liquid N/A
Not yet recruiting NCT06332807 - AAV Gene Therapy Clinical Study in Adult Classic PKU Phase 1/Phase 2
Completed NCT00225615 - A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels Phase 3
Recruiting NCT05128149 - Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?
Terminated NCT05229549 - Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria N/A
Enrolling by invitation NCT05356377 - Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU
Not yet recruiting NCT06337864 - Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria N/A